Search

everythinglearnresearchcommunity

for

Search:↓

Some dermatologists in Saudi Arabia prescribe Tofacitinib for hair loss, but many don't due to its unavailability and safety concerns.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

As of 1994, treatments for liver cancer had not significantly improved patient survival.

Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.

Tofacitinib helped a 19-year-old regrow hair after other treatments failed.

Tofacitinib helped a woman regrow hair with no major side effects.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

Ritlecitinib effectively regrows hair in adolescents with alopecia areata and is safe.

Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.

Erlotinib can cause hair loss and texture changes.

Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.

ONO-3403 effectively reduces mouse skin tumor growth without side effects.

Reducing gefitinib dosage improved hair loss, but scarring remained.

Ritlecitinib is generally safe for long-term use, with mostly mild side effects.

Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.

A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.

Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.

Personalized treatment based on detailed tumor analysis successfully managed and reduced the patient's aggressive hair follicle cancer.

MK-5108 is safe and shows potential against tumors, especially alone.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.

Gefitinib can cause hair and eyebrow darkening.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Nilotinib can cause skin issues like red bumps and hair loss.